
Newsletter
Promoter: | ShiznitStocks | Paying Party: | UNKNOWN |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
IBIO | Unknown compensation | UNKNOWN |
Max Profit: 11.69 % | Gain at close: 2.41 % | |
*We think that this promoter is a part of a group of promoters. |

Morning,
I hope our alert in IBIO today has made up for yesterday.
IBIO opened at $0.40 and climbed slowly to hit a high this morning of $0.4690 for a very achievable 17% gain.
Of course we are always looking for more gains, but IBIO gave us a nice steady winner.
Keep watching this throughout the day though, it's very liquid, and there may be dip buying opportunities and further gains to be had.
All the best.
ShiznitStocks.com
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Hello fellow investors / traders,
Last night I promised you a big board momentum trade, and here it is.
Get iBio Inc (IBIO) on your screen now. Let me start by saying this... Do not chase a large gap up. We don't expect one, but if there is, be patient.
Now look at the chart below and see the strong sideways consolidation and recent support at $0.35, just below the current price.
The chart shows possible resistance at $0.45, but after that the next stop could be in the mid $0.50's
We see strong potential gains in IBIO with a solid risk v reward trading profile.
iBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com - See more at: http://www.noodls.com/view/3F2AB09A0DA987F6C05A9C7FAD69FB0D38A2E96A#sthash.nm65oLZi.dpufiBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com - See more at: http://www.noodls.com/view/3F2AB09A0DA987F6C05A9C7FAD69FB0D38A2E96A#sthash.nm65oLZi.dpufiBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com - See more at: http://www.noodls.com/view/3F2AB09A0DA987F6C05A9C7FAD69FB0D38A2E96A#sthash.nm65oLZi.dpufiBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com - See more at: http://www.noodls.com/view/3F2AB09A0DA987F6C05A9C7FAD69FB0D38A2E96A#sthash.nm65oLZi.dpufiBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.
The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production.
Further information is available at their website: www.ibioinc.com
iBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com - See more at: http://www.noodls.com/view/3F2AB09A0DA987F6C05A9C7FAD69FB0D38A2E96A#sthash.nm65oLZi.dpuf
Make sure you get IBIO on your screen now, this could move fast today.
Disclaimer Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. For full disclaimer click here. |